Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001493152-22-016599
Filing Date
2022-06-13
Accepted
2022-06-13 17:24:27
Documents
73
Period of Report
2022-04-30

Document Format Files

Seq Description Document Type Size
1 form6-k.htm   iXBRL 6-K 22148
2 ex99-1.htm   iXBRL EX-99.1 767276
3 ex99-2.htm EX-99.2 601543
4 ex99-1_001.jpg GRAPHIC 17383
5 ex99-2_001.jpg GRAPHIC 14443
6 ex99-2_002.jpg GRAPHIC 3408
7 ex99-2_003.jpg GRAPHIC 47258
8 ex99-2_004.jpg GRAPHIC 19102
  Complete submission text file 0001493152-22-016599.txt   5632058

Data Files

Seq Description Document Type Size
9 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bctx-20220430.xsd EX-101.SCH 61285
10 INLINE XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bctx-20220430_cal.xml EX-101.CAL 57817
11 INLINE XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bctx-20220430_def.xml EX-101.DEF 164313
12 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bctx-20220430_lab.xml EX-101.LAB 340836
13 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bctx-20220430_pre.xml EX-101.PRE 270827
67 EXTRACTED XBRL INSTANCE DOCUMENT form6-k_htm.xml XML 909439
Mailing Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1
Business Address 3RD FLOOR, BELLEVUE CENTRE, 235-15TH STR WEST VANCOUVER A1 V7T 2X1 (604) 921-1810
BriaCell Therapeutics Corp. (Filer) CIK: 0001610820 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0731
Type: 6-K | Act: 34 | File No.: 001-40101 | Film No.: 221012634
SIC: 2834 Pharmaceutical Preparations